Investors and Media

Sangamo is a clinical stage biopharmaceutical company focused on the research, development and commercialization of engineered DNA-binding proteins as novel therapeutics to treat unmet medical needs. We are worldwide leaders in developing zinc finger DNA-binding proteins (ZFPs) for therapeutic gene regulation and modification. Our ZFP technology platform has multiple applications in:

  • Human Therapeutics
  • High-value Research Tools
  • Transgenic Animals
  • Cell-line Engineering for Protein Manufacturing
  • Plant Agriculture
(NASDAQ: SGMO) $6.18 - 0.16 (2.524%) High
Volume 301,773 2:01 PM ET on Jul 28, 2016 Delayed at least 20 minutes

Investor Presentation

Corporate Fact Sheet